No Picture
News

ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder

SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ClinicalTrial?src=hash" target="_blank"gt;#ClinicalTriallt;/agt;–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development … […]

No Picture
News

ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder

SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ClinicalTrial?src=hash" target="_blank"gt;#ClinicalTriallt;/agt;–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development … […]

No Picture
News

ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder

SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ClinicalTrial?src=hash" target="_blank"gt;#ClinicalTriallt;/agt;–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development … […]

No Picture
News

ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder

SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ClinicalTrial?src=hash" target="_blank"gt;#ClinicalTriallt;/agt;–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development … […]